Letter to Utah Congressional Delegation RE: H.R. 3, The Lower Drug Costs Now Act
May 25, 2021
Today, BioUtah, in conjunction with Centro Civico Mexicano, First Step House, International Cancer Advocacy Network, Mental Healthy FIT, Northern Utah Coalition, and Patel Family Investments, sent a letter to Utah’s congressional delegation expressing concern with the reintroduction of H.R. 3, The Lower Drug Costs Now Act. In the letter, the coalition states its concern about the bill’s negative impact on investment in drug discovery.
You may read the letter in its entirety here.
Recent News
- Myriad Genetics Highlights New Research Advancements and Oncology Innovations at 2025 ASCO Annual Meeting
- BD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease
- Lessons in Innovation: Clark Turner’s Impact on Medical Imaging
- Merit Medical Acquires Biolife Delaware
- Pathos AI Secures $365 Million in Series D Financing to Advance Oncology Drug Development Through AI
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
